Diagnostic Biochips announced a neural probe technology for functional electrophysiology in organoid screening that promises higher predictive validity in early‑stage drug testing. Company leadership says the platform captures activity from complex neural organoids to better model human physiology and identify non‑efficacious or toxic candidates earlier. By integrating functional readouts with organoid models, the technology aims to reduce late‑stage clinical attrition and accelerate target validation. The approach targets neural diseases and psychiatric indications where electrical activity is a primary functional endpoint.